Institute Paoli-Calmettes

Marseille 13009

0 studies enrolling now · 9 studies all time

What they study most

Bladder Carcinoma in Situ (CIS), Chronic Myelomonocytic Leukemia, Cytopenia, GIST, HER2-positive Breast Cancer, MDS, Metastasis From Malignant Tumor of Prostate, Myelodysplastic Syndromes, Pancreatic Cancer, Prostate Cancer Metastatic, RAEB, Refractory Anemia With Excess Blasts

Studies at this site

• Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID) — Running, not enrolling
• PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer — Running, not enrolling
• 177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer — Running, not enrolling
• Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer — Running, not enrolling
• ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study — Completed
• (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST — Completed
• Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine — Completed
• Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts — Completed
• A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care — Completed